Navigation Links
Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 16, 2009

BASKING RIDGE, N.J., Nov. 10 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at Biotech 2009 held at the Pennsylvania Convention Center in Philadelphia, Pennsylvania. Ms. McDonald's presentation will be given at 10:15am (EST) on Monday, November 16 and will include an overview of the Company's pipeline with emphasis on the lead development program, the anticoagulant system, REG1. In its ninth year, this annual joint symposium of BioNJ and Pennsylvania Bio is designed to advance the growth and development of the bioscience industry in this geographic region.


Regado Biosciences is pioneering a new therapeutic technology with the creation and development of two-component drug systems. Each system comprises a nuclease-stabilized RNA aptamer that can be controlled directly by its specific and complementary oligonucleotide active control agent. This technology is being applied to injectable antithrombotics, including anticoagulants and antiplatelet agents, a multi-billion dollar market in need of therapeutics with improved safety profiles and a greater degree of therapeutic control. Regado's technology is designed to give physicians the ability to actively and directly control each system's therapeutic effect providing a safe and unique approach to personalized medicine.


Regado's lead program, the anticoagulant system REG1, consists of two parenteral agents both administered by IV bolus, the first being a potent highly selective Factor IXa inhibitor (RB006) and the second being its complementary active control agent (RB007). RB007 can be used to selectively completely or partially reverse the anticoagulant effect of RB006. REG1, presently in phase 2b clinical trial, is intended for application in arterial thrombosis applications, initially in Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention. REG2, Regado's second product candidate, consists of a subcutaneously administered formulation of RB006 paired with the IV bolus formulation of RB007. REG2 is currently undergoing phase 1 clinical testing and is intended for use in venous thrombosis indications


RB006 is a member of a class of compounds called aptamers. Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein. A key unique feature of aptamers derives from the fact that they are formed from nucleic acids. As such, their pharmacologic activity can be controlled by a matched, complementary oligonucleotide active control agent (the Watson-Crick base pair complement of a fraction of the agent to be controlled), which can bind to the aptamer, removing it from its target and reversing it biologic effects.

More information can be found at

SOURCE Regado Biosciences

SOURCE Regado Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Regado Biosciences To Present at the 2009 Japan Biopharma Partnering Conference on October 6, 2009
2. Regado Biosciences Announces Allowance in Europe of a Fundamental Patent Broadly Covering Oligonucleotide Modulators to Blood Coagulation Factor Aptamers
3. Regado Biosciences to Present at the BioPharm America 2009 Conference on September 17, 2009
4. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
5. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
6. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
7. Regado Biosciences Expands Medical Advisory Board
8. Regado Biosciences Establishes Medical Advisory Board
9. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
10. Regado Biosciences To Present at the 27th Annual J.P. Morgan Healthcare Conference
11. Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Post Your Comments:
(Date:11/30/2015)... and PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult stem ... subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional ... Office of the Chief Scientist (OCS). This grant, the second ... for 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/26/2015)... , England , November 26, 2015 /PRNewswire/ ... Medical, an innovative medical device company specializing in imaging technologies, ... from the European Commission as part of the Horizon 2020 ... company to carry out a large-scale clinical trial in breast ...      (Logo: , --> ...
(Date:11/25/2015)... 2 nouvelles études permettent d ... différences entre les souches bactériennes retrouvées dans la plaque ... humains . Ces recherches  ouvrent une nouvelle ... charge efficace de l,un des problèmes de santé ... .    --> 2 nouvelles études permettent d ...
Breaking Biology Technology:
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... 29, 2015 Today, LifeBEAM , ... with 2XU, a global leader in technical performance ... hat with advanced bio-sensing technology. The hat will ... monitor key biometrics to improve overall training performance. ... two companies will bring together the most advanced technology, ...
Breaking Biology News(10 mins):